DPIIT and Pfizer Partner to Boost Healthcare Innovation in India

In a move to accelerate healthcare innovation in India, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, signed a Memorandum of Understanding (MoU) with Pfizer Limited. 

This collaboration aims to foster innovation by supporting startups working in the MedTech space with both financial and non-financial assistance.

Pfizer INDovation Program: Empowering Startups

The partnership will extend the Pfizer INDovation program to DPIIT-recognised startups, providing grants of up to ₹60 lakhs each. Additionally, selected startups will undergo an 18-month tailored incubation program led by Social Alpha, with specialised tracks covering clinical validation, regulatory clearances, and go-to-market strategies.

Startups will also receive mentorship, access to global healthcare networks, and exposure at Pfizer’s R&D facility in Chennai, giving them a competitive edge to refine their innovations.

Focus Areas of the Initiative

The initiative will support 14 pioneering MedTech startups working in areas such as screening, diagnostics, health monitoring, and treatment enablers. Special emphasis will be placed on tackling non-communicable diseases, oncology, brain health, maternal and child health, and immunisation.

Also Read: Best Debt Free Stocks in September 2025!

Industry Leaders Speak

Speaking at the event, Shri Sanjiv, Joint Secretary at DPIIT, highlighted the importance of moving towards novel drug discovery and the critical role of startups in this transformation. Meanwhile, Shri Sharad Goswami, Senior Director – Global Policy and Public Affairs, Pfizer India, emphasised Pfizer’s commitment to enabling patient-centric healthcare solutions for India.

Conclusion

This MoU reflects a strong public–private partnership model aimed at positioning India as a global hub for healthcare innovation, while also empowering startups to deliver impactful solutions tailored to local needs.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.